In This Article:
As trade tensions between the U.S. and China continue to escalate, impacting global markets, Asian small-cap stocks have been navigating a complex environment marked by volatility and cautious investor sentiment. Despite these challenges, opportunities may arise for discerning investors who focus on companies with strong fundamentals and potential for growth in this dynamic region.
Top 10 Undervalued Small Caps With Insider Buying In Asia
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
Security Bank | 4.6x | 1.1x | 40.77% | ★★★★★★ |
New Hope | 5.5x | 1.6x | 48.98% | ★★★★★☆ |
Atturra | 26.4x | 1.1x | 42.17% | ★★★★★☆ |
Viva Energy Group | NA | 0.1x | 41.56% | ★★★★★☆ |
Dicker Data | 19.0x | 0.7x | -35.59% | ★★★★☆☆ |
Sing Investments & Finance | 7.4x | 3.7x | 41.49% | ★★★★☆☆ |
PWR Holdings | 36.3x | 5.0x | 21.25% | ★★★☆☆☆ |
Hansen Technologies | 298.5x | 2.9x | 22.20% | ★★★☆☆☆ |
WAM Strategic Value | 9.2x | 5.3x | 1.71% | ★★★☆☆☆ |
Integral Diagnostics | 147.7x | 1.7x | 44.24% | ★★★☆☆☆ |
Let's dive into some prime choices out of from the screener.
HMC Capital
Simply Wall St Value Rating: ★★★★★☆
Overview: HMC Capital is a company engaged in real estate operations, with a market cap of A$1.58 billion.
Operations: The company's revenue primarily stems from real estate activities, with a significant portion of its income influenced by segment adjustments. Over time, the gross profit margin has reached 100%, indicating that revenue equals gross profit due to the absence of reported cost of goods sold (COGS). Operating expenses have consistently increased, reflecting a focus on managing non-operating expenses effectively. The net income margin has shown significant improvement, reaching 112.27% in recent periods.
PE: 8.9x
HMC Capital, a small company in Asia, is drawing attention due to its interest in acquiring Healthscope Limited, aiming to protect rents for its HealthCo REIT. Despite higher-risk funding from external borrowing, the company reported significant earnings growth with net income reaching A$166.9 million for the half-year ended December 2024. Insider confidence is evident from recent share purchases within the last year. The company's revenue is forecasted to grow annually by 12.29%, suggesting potential future opportunities despite current challenges.
-
Delve into the full analysis valuation report here for a deeper understanding of HMC Capital.
-
Understand HMC Capital's track record by examining our Past report.
China XLX Fertiliser
Simply Wall St Value Rating: ★★★★★☆
Overview: China XLX Fertiliser is a company engaged in the production and sale of chemical fertilizers and related products, with a focus on urea, methanol, and compound fertilizers, holding a market capitalization of CN¥7.57 billion.